Celltrion signed an agreement with California-based Rani Therapeutics to jointly develop an oral version of Adalimumab as part of efforts to tap into the approximately $20-billion market.
With Humira, the world’s top-selling drug for over a decade, losing its monopoly, Korean biosimilar makers are gearing up to tap into the approximately $20-billion market.
Korea JoongAng Daily Sitemap